Intrahepatic cholangiocarcinomas make up approximately 10% to 20% of cases with a low to high prevalence of K-Ras mutations, while extrahepatic cholangiocarcinomas have a much higher rate of about 40% to 60% of cases46. The gene discussed is KRAS; the disease is intrahepatic cholangiocarcinoma.